Search results for ''

Le Progrès – Enyo Pharma lève 40 millions d’euros

https://www.leprogres.fr/economie/2018/06/04/enyo-pharma-leve-40-millions-d-euros

Published on 04/06/2018

ENYO Pharma raises €40 million in Series B fundraising

Lyon, June 4, 2018 – ENYO Pharma, a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, today announced that it has completed a €40 million Series B round of financing from US and European investors. This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic HBV and NASH. A second asset is also planned to enter clinic by 2019.

Read more »

Published on 04/06/2018

Posters presentation with Novadiscovery and Calvagone at the PAGE Meeting

ENYO Pharma is pleased to collaborate with Novadiscovery and Calvagone which will present the first in silico liver disease model and the pharmackinetics-pharmacodynamics analysis respectivelly of EYP001 treatment effect on Hepatitis B virus (HBV) infected patients at the PAGE Meeting, May 29th – June 1st, 2018 in Switzerland.

Read more »

Published on 31/05/2018

ENYO Pharma rewarded for the best MEET2WIN 2018 pitch

https://matwin.fr/wp-content/uploads/2018/05/CP-post-Board-MATWIN-2018-GB.pdf

Published on 29/05/2018

MIMESIS Newsletter #3: A novel systems biology approach to develop preclinical assets

MIMESIS NEWSLETTER #3, April 2018

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.

Read more »

Published on 26/04/2018